Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab

BACKGROUND: Up to 30% of patients with food allergies have clinical reactivity to more than one food allergen. Although there is currently no cure, oral immunotherapy (OIT) is under investigation. Pilot data have shown that omalizumab may hasten the ability to tolerate over 4 g of food allergen prot...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Bégin, Philippe, Dominguez, Tina, Wilson, Shruti P, Bacal, Liane, Mehrotra, Anjuli, Kausch, Bethany, Trela, Anthony, Tavassoli, Morvarid, Hoyte, Elisabeth, O’Riordan, Gerri, Blakemore, Alanna, Seki, Scott, Hamilton, Robert G, Nadeau, Kari C
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2014
Предметы:
Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3936817/
https://ncbi.nlm.nih.gov/pubmed/24576338
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1710-1492-10-7
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы